Standalone 29-MHz micro-ultrasound for classifying clinically significant prostate cancer: a systematic review and diagnostic test accuracy meta-analysis of prospective studies
Authors:
- Ahmed M. Abdel GawadAGAhmed M. Abdel Gawad
- Ahmed Y. AboelsaadAAAhmed Y. Aboelsaad
- Ahmed Fawzi ElsayedAEAhmed Fawzi Elsayed
- Elsayed Mohamed Abd El-Hamid HassanEHElsayed Mohamed Abd El-Hamid Hassan
- Ahmed Yahia AshourAAAhmed Yahia Ashour
- Alshimaa Yahia AshourAAAlshimaa Yahia Ashour
- Eman M. El-DydamonyEEEman M. El-Dydamony
- Maha M. ElzamekMEMaha M. Elzamek
- Amany Ahmed SolimanASAmany Ahmed Soliman
- Hany ElsegeayHEHany Elsegeay
- Ahmed Farag WahshAWAhmed Farag Wahsh
- Mohamed Fathy ElebiaryMEMohamed Fathy Elebiary
Open Access
- 31 October 2025
- journal article
- review article
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (6) , 2979-2992
Abstract
Background: Micro-ultrasound (micro-US; 29-MHz) offers real-time, high-resolution prostate imaging, but its stand-alone diagnostic accuracy remains uncertain. We synthesized prospective evidence to evaluate micro-US for classifying clinically significant prostate cancer (csPCa) using histopathology as the reference standard. Methods: We searched PubMed, Embase, Scopus, and Web of Science (inception–20 May 2025) for prospective studies assessing micro-US as an index test on a diagnostic pathway. Data were pooled using random-effects models on logit-transformed sensitivity and specificity, with an HSROC representation and model diagnostics. Subgroup and meta-regression analyses explored heterogeneity, including threshold (PRI-MUS) and spectrum effects. Clinical utility was appraised using Fagan nomograms and a likelihood-ratio scatter. Small-study effects were evaluated with Deeks’ test. Results: Five prospective studies met criteria. Pooled sensitivity was 0.84 (95% CI 0.65–0.94) and pooled specificity was 0.41 (95% CI 0.25–0.59), indicating moderate discrimination on HSROC. Secondary metrics were concordant (PLR 1.45, 95% CI 1.17–1.80; NLR 0.37, 95% CI 0.23–0.61; DOR 3.95, 95% CI 2.48–6.30). On a 25% pre-test probability, the Fagan nomogram showed modest shifts (~ 33% after a positive test; ~11% after a negative), supporting a triage/rule-out role. Heterogeneity was substantial and strongly influenced by threshold and clinical spectrum differences; subgroup and meta-regression suggested that spectrum-related factors were associated with lower specificity, whereas no covariate robustly altered sensitivity (exploratory given small k). Model checks were acceptable, and Deeks’ test showed no evidence of small-study effects ( p ≈ 0.70). Conclusion: As a stand-alone index test for csPCa classification, micro-US demonstrates high sensitivity but low specificity, yielding modest impact on post-test probability. These findings support micro-US as a complementary/triage (rule-out) adjunct, particularly when mpMRI is unavailable, contraindicated, or delayed, while highlighting the need for standardized PRI-MUS thresholds, reader training, and larger multicenter studies to refine specificity and clarify integration with MRI-based pathways.Keywords
Funding Information
- Al-Azhar University
This publication has 26 references indexed in Scilit:
- The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysisEuropean Urology, 2025
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2024
- Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP TrialPharmacoEconomics, 2022
- Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and DiagnosisValue in Health, 2022
- Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective StudyEuropean Urology Focus, 2021
- A multi‐institutional randomized controlled trial comparing first‐generation transrectal high‐resolution micro‐ultrasound with conventional frequency transrectal ultrasound for prostate biopsyBJUI Compass, 2020
- PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancerClinical and Translational Oncology, 2020
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessedJournal of Clinical Epidemiology, 2005